Insulet (NASDAQ:PODD) & PAVmed (NASDAQ:PAVM) Head-To-Head Review

Insulet (NASDAQ:PODD) and PAVmed (NASDAQ:PAVM) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations.

Risk & Volatility

Insulet has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, PAVmed has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Institutional and Insider Ownership

19.9% of PAVmed shares are owned by institutional investors. 0.5% of Insulet shares are owned by insiders. Comparatively, 11.3% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Insulet and PAVmed”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.07 billion	9.14	$206.30 million	$5.79	46.58
PAVmed	$4.03 million	1.81	-$64.18 million	($4.35)	-0.15

Insulet has higher revenue and earnings than PAVmed. PAVmed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Insulet and PAVmed, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	0	3	13	0	2.81
PAVmed	0	0	1	1	3.50

Insulet presently has a consensus price target of $289.06, indicating a potential upside of 7.18%. PAVmed has a consensus price target of $19.00, indicating a potential upside of 2,778.79%. Given PAVmed’s stronger consensus rating and higher possible upside, analysts plainly believe PAVmed is more favorable than Insulet.

Profitability

This table compares Insulet and PAVmed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Insulet	20.19%	24.46%	8.33%
PAVmed	602.97%	N/A	-92.36%

Summary

Insulet beats PAVmed on 9 of the 15 factors compared between the two stocks.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

About PAVmed

PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.